Search results

696 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

In development [GID-TA10611] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bulevirtide for treating chronic hepatitis D [ID3732]

In development [GID-TA10652] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

In development
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation

In development [GID-MT554] Expected publication date: 06 January 2022

Type

Medical technologies guidance

Status

In development
Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (update of DG21) (provisional title)

In development [GID-DG10042] Expected publication date: 13 April 2022

Type

Diagnostics guidance

Status

In development
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

In development [GID-MT557] Expected publication date: 22 March 2022

Type

Medical technologies guidance

Status

In development
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]

In development [GID-TA10538] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]

In development [GID-TA10705] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Nitisinone for treating alkaptonuria [ID2691]

Proposed [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
MT507 Plus Sutures for preventing surgical site infection

In development [GID-MT558] Expected publication date: 09 November 2021

Type

Medical technologies guidance

Status

In development
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]

In development [GID-TA10766] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862]

In development [GID-TA10744] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

In development [GID-TA10742] Expected publication date: 05 January 2022

Type

Technology appraisal guidance

Status

In development
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
GID-MT561 ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections

In development [GID-MT561] Expected publication date: 02 February 2022

Type

Medical technologies guidance

Status

In development
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]

In development [GID-TA10725] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - lubiprostone [ID646]

In development [GID-TAG367] Expected publication date: 01 October 2014

Type

Technology appraisal guidance

Status

In development
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: 22 December 2021

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]

In development [GID-TA10417] Expected publication date: 15 September 2021

Type

Technology appraisal guidance

Status

In development
Ofatumumab for treating relapsing multiple sclerosis [ID1677]

In development [GID-TA10557] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]

In development [GID-TA10584] Expected publication date: 05 May 2021

Type

Technology appraisal guidance

Status

In development
Dapagliflozin for treating chronic kidney disease [ID3866]

Proposed [GID-TA10808] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

In development [GID-TA10526] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

In development [GID-TA10334] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development